-
Electronic (PDF)
-
Site License
-
Enterprisewide
Polio - Pipeline Review, H2 2011
Global Markets Direct, October 2011, Pages: 62
Polio - Pipeline Review, H2 2011
Summary
Global Markets Direct’s, 'Polio - Pipeline Review, H2 2011', provides an overview of the Polio therapeutic pipeline. This report provides information on the therapeutic development for Polio, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polio. 'Polio - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Polio.
- A review of the Polio products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Polio pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Polio.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Polio pipeline depth and focus of Polio therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polio Overview
Therapeutics Development
An Overview of Pipeline Products for Polio
Polio Therapeutics under Development by Companies
Polio Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Polio Therapeutics - Products under Development by Companies
Polio Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Polio Therapeutics Development
Sanofi-Aventis
GlaxoSmithKline plc
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited
Mitsubishi Tanabe Pharma Corporation
Polio - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Xepol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2036874A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rotarix + Infanrix + Pediarix + GSK 208108 + Prevnar 13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK2202083A + Synflorix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DTaP-IPV-HB-PRP~T + Prevnar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Inactivated Poliomyelitis Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Heptavalent Combination Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hexavalent Combination Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK217744 Formulation B + Prevenar 13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK217744 Formulation A + Prevenar 13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hexaxim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Quadracel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rotarix + Infanrix + Oral Poliovirus Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BK-4SP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V419 + Pentacel + Prevnar 13 + RotaTeq - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Infanrix Hexa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DTP-HepB-Polio-Hib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP059 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V419 + Daptacel + PedvaxHIB + Prevnar 13 + RotaTeq - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KD-332 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-361S - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Polio Therapeutics – Drug Profile Updates
Polio Therapeutics - Discontinued Products
Polio - Featured News
Oct 26, 2000: Hexavalent pediatric vaccines licensed in EU
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
